These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39220196)

  • 1. Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth.
    Shaji SG; Patel P; Mamani UF; Guo Y; Koirala S; Lin CY; Alahmari M; Omoscharka E; Cheng K
    Int J Nanomedicine; 2024; 19():8769-8778. PubMed ID: 39220196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
    Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
    Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases.
    Liu Y; Crowe WN; Wang L; Lu Y; Petty WJ; Habib AA; Zhao D
    Nat Commun; 2019 Nov; 10(1):5108. PubMed ID: 31704921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
    Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
    Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.
    Da Y; Liu Y; Hu Y; Liu W; Ma J; Lu N; Zhang C; Zhang C
    Oncoimmunology; 2022; 11(1):2054105. PubMed ID: 35371622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation.
    Luo Z; Liang X; He T; Qin X; Li X; Li Y; Li L; Loh XJ; Gong C; Liu X
    J Am Chem Soc; 2022 Sep; 144(36):16366-16377. PubMed ID: 36037283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
    Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
    Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.
    Lai J; Fu Y; Tian S; Huang S; Luo X; Lin L; Zhang X; Wang H; Lin Z; Zhao H; Lin S; Zhao J; Xu S; Li D; Cai S; Dong L; Qian J; Liang J; Li Q; Zhang Y; Fan J; Balderas R; Chen Q
    Mol Ther; 2021 May; 29(5):1758-1771. PubMed ID: 33571681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
    Li K; Ye Y; Liu L; Sha Q; Wang X; Jiao T; Zhang L; Wang J
    Biomater Sci; 2021 Feb; 9(3):765-773. PubMed ID: 33201161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer.
    Chibaya L; DeMarco KD; Lusi CF; Kane GI; Brassil ML; Parikh CN; Murphy KC; Chowdhury SR; Li J; Ma B; Naylor TE; Cerrutti J; Mori H; Diaz-Infante M; Peura J; Pitarresi JR; Zhu LJ; Fitzgerald KA; Atukorale PU; Ruscetti M
    Sci Transl Med; 2024 Aug; 16(762):eadj9366. PubMed ID: 39196958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.
    Junkins RD; Gallovic MD; Johnson BM; Collier MA; Watkins-Schulz R; Cheng N; David CN; McGee CE; Sempowski GD; Shterev I; McKinnon K; Bachelder EM; Ainslie KM; Ting JP
    J Control Release; 2018 Jan; 270():1-13. PubMed ID: 29170142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response.
    Li T; Cheng H; Yuan H; Xu Q; Shu C; Zhang Y; Xu P; Tan J; Rui Y; Li P; Tan X
    Sci Rep; 2016 Jan; 6():19049. PubMed ID: 26754564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of STING agonist with anti-vascular RGD-(KLAKLAK)
    Czapla J; Drzyzga A; Ciepła J; Matuszczak S; Jarosz-Biej M; Pilny E; Cichoń T; Smolarczyk R
    Cancer Immunol Immunother; 2024 Jun; 73(8):148. PubMed ID: 38832958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways.
    Johnson BM; Uchimura T; Gallovic MD; Thamilarasan M; Chou WC; Gibson SA; Deng M; Tam JW; Batty CJ; Williams J; Matsushima GK; Bachelder EM; Ainslie KM; Markovic-Plese S; Ting JP
    J Immunol; 2021 May; 206(9):2015-2028. PubMed ID: 33820855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
    Lu ZD; Chen YF; Shen S; Xu CF; Wang J
    ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
    Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
    J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.
    Koshy ST; Cheung AS; Gu L; Graveline AR; Mooney DJ
    Adv Biosyst; 2017 Feb; 1(1-2):. PubMed ID: 30258983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.